Codexis (CDXS) Insider Dilly Stephen George Buys 66,350 Shares

Multiple Insiders Expand Holdings on the Same Day

A group of six company insiders, including Stephen George Dilly, Raymond De Vre, Cynthia Collins, Esther Martinborough, Rahul Singhvi, David Smith, and Stewart Parker, each picked up identical blocks of 66,350 shares of Codexis, Inc. (NasdaqGS: CDXS) on June 17, 2026. This coordinated group of purchases adds a notable volume of shares to insider hands all at once. The shared transaction date and exact block size point to a coordinated equity alignment across the leadership team.

Stock Trades Near Highs for the Year

Codexis shares changed hands at $2.57 on the open market around the time of these filings. That puts the stock comfortably above its 52-week low of $0.96 and right near the top of its yearly trading range, which tops out at $2.98. The company carries a market capitalization of roughly $151.1 million, reflecting its status as a smaller biotechnology player.

Earnings and Financial Position

Codexis reported annual revenue of $77.68 million with a minor revenue growth contraction of 2.7%. The biotech firm posted a negative earnings per share of $0.33. Because the firm isn't profitable right now, it has no traditional price-to-earnings ratio, though its forward P/E rests at -4.31. Investors tracking the operational timeline can look forward to the company's next earnings report, which is scheduled for November 5, 2026.

Piper Sandler Adjusts Price Target

Piper Sandler weighed in on the stock with an updated view on August 17, 2026. The firm maintained its overweight rating on Codexis while lowering its price target from $9.00 to $8.00. Across the wider analyst community, the stock holds a consensus buy recommendation drawn from seven analyst opinions, featuring a mean price target of $6.14 with a high estimate of $11.00 and a low estimate of $2.00.

Inside the Business Operations

Headquartered in Redwood City, California, Codexis focuses on discovery and manufacturing solutions for therapeutics. The firm relies on its proprietary CodeEvolver technology platform to engineer and commercialize novel enzymes. It also develops the ECO Synthesis platform to help manufacture RNAi therapeutics at scale through enzymatic routes, backed by various commercial partnerships.

What to Watch at Codexis, Inc.

Market participants will keep an eye on upcoming regulatory filings and Form 4 updates to see if other members of management add to their holdings. The next major financial checkpoint arrives with the Q3 earnings release on November 5, 2026, which will offer updated figures on revenue and research spending.